Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.JHEP.2018.06.008 | ||||
| Año | 2018 | ||||
| Tipo | revisión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
The global epidemic of obesity has been accompanied by a rising burden of non-alcoholic fatty liver disease (NAFLD), with manifestations ranging from simple steatosis to non-alcoholic steatohepatitis, potentially developing into hepatocellular carcinoma. Although much attention has focused on NAFLD, its pathogenesis remains largely obscure. The hallmark of NAFLD is the hepatic accumulation of lipids, which subsequently leads to cellular stress and hepatic injury, eventually resulting in chronic liver disease. Abnormal lipid accumulation often coincides with insulin resistance in steatotic livers and is associated with perturbed endoplasmic reticulum (ER) proteostasis in hepatocytes. In response to chronic ER stress, an adaptive signalling pathway known as the unfolded protein response is triggered to restore ER proteostasis. However, the unfolded protein response can cause inflammation, inflammasome activation and, in the case of non-resolvable ER stress, the death of hepatocytes. Experimental data suggest that the unfolded protein response influences hepatic tumour development, aggressiveness and response to treatment, offering novel therapeutic avenues. Herein, we provide an overview of the evidence linking ER stress to NAFLD and discuss possible points of intervention. (C) 2018 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Lebeaupin, Cynthia | Mujer |
Univ Cote Azur - Francia
Centre Méditerranéen de Médecine Moléculaire - Francia Université Côte d'Azur - Francia |
| 2 | Vallee, Deborah | Mujer |
Univ Cote Azur - Francia
Centre Méditerranéen de Médecine Moléculaire - Francia Université Côte d'Azur - Francia |
| 3 | Hazari, Younis M. | - |
Universidad de Chile - Chile
Centro de Gerociencia, Salud Mental y Metabolismo - Chile |
| 4 | HETZ-FLORES, CLAUDIO ANDRES | Hombre |
Universidad de Chile - Chile
Centro de Gerociencia, Salud Mental y Metabolismo - Chile Buck Inst Res Aging - Estados Unidos Harvard Sch Publ Hlth - Estados Unidos Buck Institute for Age Research - Estados Unidos Harvard T.H. Chan School of Public Health - Estados Unidos |
| 5 | Chevet, Eric | Hombre |
Univ Rennes - Francia
Ctr Lutte Canc Eugene Marquis - Francia INSERM - Francia Centre de Lutte Contre le Cancer Eugène Marquis - Francia Chemistry Oncogenesis Stress Signaling (COSS) - Francia |
| 6 | Bailly-Maitre, Beatrice | Mujer |
Univ Cote Azur - Francia
Centre Méditerranéen de Médecine Moléculaire - Francia Université Côte d'Azur - Francia |
| Fuente |
|---|
| FONDECYT |
| Fondef |
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| European Commission |
| Fondo de Fomento al Desarrollo Científico y Tecnológico |
| Millennium Institute |
| Air Force Office of Scientific Research |
| National Research Agency |
| Muscular Dystrophy Association |
| Ligue contre le Cancer |
| Fondo Nacional de Desarrollo Científico, Tecnológico y de Innovación Tecnológica |
| Agence Nationale de la Recherche |
| ARC |
| FONDAP program |
| ALSRP Therapeutic Idea Award |
| Michael J Fox Foundation for Parkinson's Research - Target Validation grant |
| European Commission RD MSCA-RISE |
| U.S. Air Force Office of Scientific Research |
| US Office of Naval Research-Global (ONR-G) |
| Michael J. Fox Foundation for Parkinson's Research |
| Horizon 2020 Framework Programme |
| CONICYT-Brazil |
| Muscular Dystrophy Association 382453 |
| US Office of Naval Research-Global |
| Institut National du Cancer (INCA) |
| AFEF |
| Association Française pour l'Etude du Foie |
| EU H2020 MSCA |
| Institut National Du Cancer |
| Multiple Sclerosis Center of Atlanta |
| EU H2020 MSCA ITN-675448 |
| Association pour la recherche sur le cancer |
| French government |
| Fondation ARC pour la Recherche sur le Cancer |
| SFD |
| "La Ligue Contre le Cancer |
| French Government (National Research Agency, ANR) through the 'Investments for the Future' LABEX SIGNALIFE: program |
| Societe Francophone du Diabete |
| ONR-G |
| European Commission R&D MSCA-RISE |
| Michael J Fox Foundation for Parkinson’s Research – Target Validation |
| National Radio Research Agency |
| H2020 MSCA |
| French Muscular Dystrophy Association |
| Azərbaycan Respirator Cəmiyyəti |
| Agradecimiento |
|---|
| This work was funded by AFEF, SFD and ARC (20171206287) (BBM), "La Ligue Contre le Cancer (DV), the French Government (National Research Agency, ANR) through the 'Investments for the Future' LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01 and #ANR-15-CE14-0016-01 (CL), and funded by grants from Institut National Du Cancer (INCa; PLBIO: 2017, PLBIO: 2015-111, INCA_7981), EU H2020 MSCA ITN-675448 (TRAINERS) and MSCA RISE-734749 (INSPIRED)(EC), FONDECYT no. 3180427 (YH), FONDECYT no. 1140549, FONDAP program 15150012, Millennium Institute P09-015-F, European Commission R&D MSCA-RISE #734749 (CH). We also thank the support from Michael J Fox Foundation for Parkinson's Research - Target Validation grant No 9277, FONDEF ID16I10223, FONDEF D11E1007, US Office of Naval Research-Global (ONR-G) N62909-16-1-2003, U.S. Air Force Office of Scientific Research FA9550-16-1-0384, ALSRP Therapeutic Idea Award AL150111, Muscular Dystrophy Association 382453, and CONICYT-Brazil 441921/2016-7 (CH). |
| This work was funded by AFEF , SFD and ARC ( 20171206287 ) (BBM), “ La Ligue Contre le Cancer (DV), the French Government (National Research Agency, ANR) through the ‘Investments for the Future’ LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01 and #ANR-15-CE14-0016-01 (CL), and funded by grants from Institut National Du Cancer (INCa; PLBIO: 2017, PLBIO: 2015-111, INCA_7981), EU H2020 MSCA ITN-675448 (TRAINERS) and MSCA RISE-734749 (INSPIRED)(EC), FONDECYT no. 3180427 (YH), FONDECYT no. 1140549, FONDAP program 15150012, Millennium Institute P09-015-F, European Commission R&D MSCA-RISE #734749 (CH). We also thank the support from Michael J Fox Foundation for Parkinson’s Research – Target Validation grant No 9277, FONDEF ID16I10223, FONDEF D11E1007, US Office of Naval Research-Global (ONR-G) N62909-16-1-2003, U.S. Air Force Office of Scientific Research FA9550-16-1-0384, ALSRP Therapeutic Idea Award AL150111, Muscular Dystrophy Association 382453, and CONICYT-Brazil 441921/2016-7 (CH). |